Generation Bio Co. Share Price

Equities

GBIO

US37148K1007

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 30/04/2024 am IST 5-day change 1st Jan Change
2.85 USD -1.72% Intraday chart for Generation Bio Co. +1.42% +72.73%
Sales 2024 * 5.59M 467M Sales 2025 * 4.77M 398M Capitalization 189M 15.82B
Net income 2024 * -86M -7.18B Net income 2025 * -97M -8.1B EV / Sales 2024 * 6.35 x
Net cash position 2024 * 154M 12.86B Net cash position 2025 * - 0 EV / Sales 2025 * 39.7 x
P/E ratio 2024 *
-2.04 x
P/E ratio 2025 *
-2.19 x
Employees 174
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.51%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Generation Bio Co.

1 day-1.72%
1 week+1.42%
Current month-29.98%
1 month-29.98%
3 months+50.00%
6 months+211.71%
Current year+72.73%
More quotes
1 week
2.81
Extreme 2.81
3.22
1 month
2.70
Extreme 2.7
4.65
Current year
1.62
Extreme 1.62
4.65
1 year
0.86
Extreme 0.86
6.98
3 years
0.86
Extreme 0.86
36.72
5 years
0.86
Extreme 0.86
55.72
10 years
0.86
Extreme 0.86
55.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 01/17/01
Director of Finance/CFO 46 22/20/22
Chief Operating Officer 46 01/18/01
Members of the board TitleAgeSince
Director/Board Member 71 01/18/01
Director/Board Member 76 01/17/01
Founder 54 01/16/01
More insiders
Date Price Change Volume
29/24/29 2.85 -1.72% 808,985
26/24/26 2.9 -3.65% 92,075
25/24/25 3.01 +0.67% 156,786
24/24/24 2.99 -8.28% 114,491
23/24/23 3.26 +16.01% 213,942

Delayed Quote Nasdaq, April 30, 2024 at 01:30 am IST

More quotes
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.85 USD
Average target price
7.5 USD
Spread / Average Target
+163.16%
Consensus